@article {Vardarajan2020.01.10.20016741, author = {Badri Vardarajan and Vrinda Kalia and Jennifer Manly and Adam Brickman and Dolly Reyes-Dumeyer and Rafael Lantigua and Iuliana Ionita-Laza and Dean P. Jones and Gary W. Miller and Richard Mayeux}, title = {Differences in Plasma Metabolites Related to Alzheimer{\textquoteright}s Disease, APOE-ε4 status and Ethnicity}, elocation-id = {2020.01.10.20016741}, year = {2020}, doi = {10.1101/2020.01.10.20016741}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {INTRODUCTION We investigated metabolites in plasma to capture systemic biochemical changes associated with Alzheimer{\textquoteright}s disease (AD).METHODS Metabolites in plasma were measured in 59 AD cases and 60 healthy participants of African American (AA), Caribbean Hispanic (CH) and non-Hispanic white (NHW) ancestry using untargeted liquid-chromatography based ultra-high resolution mass spectrometry. Metabolite differences between AD and healthy, ethnic groups and APOEε4 status were analyzed. Untargeted network analysis identified pathways enriched in AD-associated metabolites.RESULTS 5,929 annotated metabolites were measured. PLS-DA analysis inferred that AD clustered separately from healthy controls (AUC=0.9816); discriminating pathways included glycerophospholipid, sphingolipid and non-essential amino acid (alanine, aspartate, glutamate) metabolism. Metabolic features in AA clustered differently from CH and NHW (AUC=0.9275), and differed between APOEε4-carriers and non-carriers (AUC=0.9972).DISCUSSION Metabolites, specifically lipids, were associated with AD, APOEε4 and ethnic group. Metabolite profiling could identify perturbed AD pathways, but genetic and ancestral background need to be considered.Competing Interest StatementThe authors have declared no competing interest.Funding StatementWHICAP. Data collection and sharing for this project was supported by the Washington Heights-Inwood Columbia Aging Project (WHICAP, PO1AG07232, R01AG037212, RF1AG054023) funded by the National Institute on Aging (NIA) and by the National Center for Advancing Translational Sciences, National Institutes of Health, through Grant Number UL1TR001873. The metabolomics work was supported by U2C ES030163 and R01 ES023839. This manuscript has been reviewed by WHICAP investigators for scientific content and consistency of data interpretation with previous WHICAP Study publications. We acknowledge the WHICAP study participants and the WHICAP research and support staff for their contributions to this study.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData will be made available through the National Institute of Aging Genetics of Alzheimer{\textquoteright}s Disease Storage Site https://www.niagads.org}, URL = {https://www.medrxiv.org/content/early/2020/01/14/2020.01.10.20016741}, eprint = {https://www.medrxiv.org/content/early/2020/01/14/2020.01.10.20016741.full.pdf}, journal = {medRxiv} }